Three Induction Treatments on Cryptococcal Meningitis
Three Induction Treatments on Cryptococcal Meningitis
Three induction treatment strategies [ voriconazole +5FC vs. amphotericin deoxycholate
 (0.4-0.5 mg/kg/d)+5FC vs. amphotericin deoxycholate (0.7-1.0 mg/kg/d)+5FC ] for HIV-infected
 patients with cryptococcal meningitis were compared.
HIV-associated cryptococcal meningitis were randomly allocated into three induction treatment
 as follow: 1) 14 days of voriconazole 200mg bid +5FC, 2) 28 days of amphotericin deoxycholate
 (0.4-0.5 mg/kg/d) +5FC ; 3）14 days of deoxycholate (0.7-1 mg/kg/d) +5FC). After induction
 treatment were finished, all groups switched into fluconazole(400mg/d) for two-month
 consolidation treatment. 14-day early fungicidal rate, 90-day mortality, side effects , and
 tolerances were compared between three groups.
Inclusion Criteria:

 1. Clinical diagnosis of HIV infection;

 2. newly diagnosed Cryptococcal Meningitis by positive India ink staining or culture
 result, or both in cerebrospinal fluid (CSF);

 3. Anti-viral treatment naïve patients

 4. anti-fungal treatment naïve patients

 Exclusion Criteria:

 1. hepatitis virus co-infection;

 2. liver cirrhosis;

 3. congestive heart failure;

 4. chronic renal disorders;

 5. chronic obstructive pulmonary disease (COPD);

 6. Tuberculosis co-infection;

 7. malignances

 8. severe mental and neurological diseases

 9. Women during pregnancy and lactation

 10. intraveneous drug user (IDU)

 11. patients with follow abnormal test results:hemoglobin < 6 g/dl, white blood cell count
 < 2000 / μl, neutrophil count < 1000 / μl, platelet count < 75000 / μl, blood amylase
 > 3 times normal level Upper limit, serum creatinine > 1.5 times normal upper limit,
 aspartate aminotransferase / alanine aminotransferase / alkaline phosphatase > 3 times
 normal upper limit, total bilirubin > 2 times normal upper limit

 12. patients who are unwilling to anticipate.